Table 1.
Variable | Lidocaine (n = 105) | Placebo (n = 97) |
---|---|---|
Age, yr | 69 (10) | 67 (10) |
Sex, % female | 34 | 23 |
Race, % white | 94 | 91 |
Weight, kg | 80 (17) | 83 (18) |
History of hypertension, % | 61 | 53 |
Previous myocardial infarction, % | 14 | 23 |
LV ejection fraction, % | 52 (9) | 52 (12) |
Preoperative statin use, % | 30 | 32 |
Preoperative antiplatelet use, % | 27 | 36 |
Surgical procedure, % | ||
CABG | 24 | 37 |
CABG + Valve | 13 | 18 |
Valve only | 61 | 45 |
Other* | 2 | 0 |
Number of grafts** | 1 (1) | 2 (2) |
Cross-clamp time, min | 94 (35) | 90 (42) |
CPB time, min | 158 (43) | 164 (60) |
Data are represented as mean (standard deviation), except where indicated; CABG = coronary artery bypass grafting; CPB = cardiopulmonary bypass; LV = left ventricular.
Two patients in the lidocaine group had additional procedures at the time of surgery.
Number of grafts is reported only for patients who underwent CABG or CABG + Valve